CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.

about

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism.

P2860

Q38604479-0D62A229-7DB2-4483-83A8-D0BE80FDC0BA

P2860

CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.

Item

http://www.wikidata.org/entity/Q39675535

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.

@en

CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.

@nl

type

Item

label

CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.

@en

CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.

@nl

prefLabel

CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.

@en

CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.

@nl

P1476

CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.

@en

P2093

Amrut V Ambardekar

http://www.w3.org/2001/XMLSchema#string

Anh Vu

http://www.w3.org/2001/XMLSchema#string

Christina L Aquilante

http://www.w3.org/2001/XMLSchema#string

JoAnn Lindenfeld

http://www.w3.org/2001/XMLSchema#string

Kimberly M Deininger

http://www.w3.org/2001/XMLSchema#string

Robert L Page

http://www.w3.org/2001/XMLSchema#string

P2860

Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase

The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation.

The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.

PharmGKB summary: cyclosporine and tacrolimus pathways

The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients.

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.

CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients.

Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients

The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations

P304

1074-1081

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CTR.12790

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27314545

http://www.w3.org/2001/XMLSchema#string

CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.

about

P2860

P2860

CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698